Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP)

To Effeciently Deliver Vaccines Directly to the Skin, Enhancing Immunogenicity

Read the full media release below.

Learn more

Posted in — Media Release


You may also like

06 October 2020

Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

16 September 2018

VC-backed women’s health company Madorra to begin clinical trials in Australia

29 May 2020

Vaxxas announces that MSD exercises option to apply novel immune system activation platform for vaccine candidate

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

16 May 2018

Biomedical Translation Fund invests in further development of total artificial heart device

26 March 2015

Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S.

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor